JP2023522716A5 - - Google Patents
Info
- Publication number
- JP2023522716A5 JP2023522716A5 JP2022563944A JP2022563944A JP2023522716A5 JP 2023522716 A5 JP2023522716 A5 JP 2023522716A5 JP 2022563944 A JP2022563944 A JP 2022563944A JP 2022563944 A JP2022563944 A JP 2022563944A JP 2023522716 A5 JP2023522716 A5 JP 2023522716A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- anticancer agent
- checkpoint inhibitor
- pharmaceutical composition
- clostridium butyricum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025174464A JP2026031928A (ja) | 2020-04-21 | 2025-10-16 | がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013141P | 2020-04-21 | 2020-04-21 | |
| US63/013,141 | 2020-04-21 | ||
| PCT/US2021/028251 WO2021216618A1 (en) | 2020-04-21 | 2021-04-20 | Compositions and methods comprising clostridium butyricum for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025174464A Division JP2026031928A (ja) | 2020-04-21 | 2025-10-16 | がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522716A JP2023522716A (ja) | 2023-05-31 |
| JP2023522716A5 true JP2023522716A5 (enExample) | 2024-04-30 |
| JP7813240B2 JP7813240B2 (ja) | 2026-02-12 |
Family
ID=78270016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563944A Active JP7813240B2 (ja) | 2020-04-21 | 2021-04-20 | がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 |
| JP2025174464A Pending JP2026031928A (ja) | 2020-04-21 | 2025-10-16 | がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025174464A Pending JP2026031928A (ja) | 2020-04-21 | 2025-10-16 | がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12589123B2 (enExample) |
| EP (1) | EP4138869A4 (enExample) |
| JP (2) | JP7813240B2 (enExample) |
| KR (1) | KR20230004604A (enExample) |
| CN (1) | CN116390737A (enExample) |
| AU (1) | AU2021261290A1 (enExample) |
| CA (1) | CA3180564A1 (enExample) |
| WO (1) | WO2021216618A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240415900A1 (en) * | 2021-10-20 | 2024-12-19 | City Of Hope | Clostridium butyricum compositions and methods of using the same |
| CN115671142A (zh) * | 2022-11-15 | 2023-02-03 | 中山大学附属第六医院 | 丁酸梭菌在结直肠癌辅助治疗上的应用 |
| CN116650534B (zh) * | 2023-03-10 | 2026-07-28 | 中南大学 | 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用 |
| CN121152637A (zh) * | 2023-05-23 | 2025-12-16 | 日本米雅利桑制药株式会社 | 癌治疗用组合药物 |
| CN116687979B (zh) * | 2023-06-28 | 2025-06-20 | 中国人民解放军陆军军医大学 | 肠道微生物在稳定肠道谷氨酰胺以及在制备治疗癌症的药物中的应用 |
| CN120131715A (zh) * | 2025-03-14 | 2025-06-13 | 中山大学孙逸仙纪念医院 | 膀胱灌注丁酸梭菌免疫制剂及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6153219A (ja) | 1984-08-23 | 1986-03-17 | Tadashi Arai | 抗腫瘍剤 |
| JP2009269836A (ja) | 2008-05-01 | 2009-11-19 | Miyarisan Pharmaceutical Co Ltd | 大腸癌細胞増殖抑制物質 |
| EP3518946A4 (en) * | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| EP3559257A1 (en) | 2016-12-22 | 2019-10-30 | Institut Gustave Roussy (IGR) | Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment |
| WO2019165285A1 (en) * | 2018-02-23 | 2019-08-29 | Crestovo Holdings Llc | Microbiome related immunotherapies |
| WO2019178542A1 (en) * | 2018-03-16 | 2019-09-19 | Persephone Biome, Inc. | Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same |
| CN109771445B (zh) | 2019-03-20 | 2022-08-05 | 青岛东海药业有限公司 | 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 |
-
2021
- 2021-04-20 JP JP2022563944A patent/JP7813240B2/ja active Active
- 2021-04-20 EP EP21793748.1A patent/EP4138869A4/en active Pending
- 2021-04-20 CN CN202180044054.6A patent/CN116390737A/zh active Pending
- 2021-04-20 CA CA3180564A patent/CA3180564A1/en active Pending
- 2021-04-20 US US17/996,779 patent/US12589123B2/en active Active
- 2021-04-20 AU AU2021261290A patent/AU2021261290A1/en active Pending
- 2021-04-20 KR KR1020227039551A patent/KR20230004604A/ko active Pending
- 2021-04-20 WO PCT/US2021/028251 patent/WO2021216618A1/en not_active Ceased
-
2025
- 2025-10-16 JP JP2025174464A patent/JP2026031928A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2024088273A1 (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| JP2022531898A5 (enExample) | ||
| JP2020536965A5 (enExample) | ||
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| Frieboes et al. | Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy | |
| WO2016091165A1 (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| WO2022007745A1 (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| JP2024502446A5 (enExample) | ||
| JP2019526559A5 (enExample) | ||
| JP2023522415A5 (enExample) | ||
| Easwaran et al. | Polmacoxib: a review of the newer non-steroidal anti-inflammatory drug in osteoarthritis | |
| CN114748480A (zh) | 一种预防和/或治疗癌症的药物组合物 | |
| CN105476996B (zh) | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 | |
| Timmins et al. | Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery | |
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| CN115624552A (zh) | 用于乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| CN105616411A (zh) | 治疗结肠癌的组合物及其应用 | |
| CN111757737B (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 | |
| WO2022048527A1 (zh) | 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 | |
| CN103893188A (zh) | 冬青素a在制备抗肿瘤药物中的用途 | |
| CN116115623A (zh) | 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用 | |
| JP2024515100A5 (enExample) | ||
| MXPA06014477A (es) | Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer. | |
| TWI868400B (zh) | 西達本胺聯合雌激素受體下調劑治療乳腺癌的用途 | |
| Stephens | “CRAB” chemotherapy: Curative, relieving, adjuvant, and basal |